Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
osimertinib (tagrisso) (3 trials)
ty-9591 (6 trials)
ty-1091 (1 trial)
tamoxifen (nolvadex) (1 trial)
ty-2136b (1 trial)
ty-2699a (1 trial)
ty-302 (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Neoplasms (Phase 1)
Trials (10 total)
Trial APIs (7 total)